Skip to main content
. 2022 Feb 3;12:1837. doi: 10.1038/s41598-022-05496-1

Table 2.

Association between serum concentration of IGF-1 and breast cancer by SNPs of genes regulating energy homeostasis, the Breast Cancer Health Disparities Study.

IGF-1 association with premenopausal breast cancer
Variables OR 95% CI P value
IGF-1 T1 1.00
IGF-1 T2 1.34 0.87, 2.04 0.18
IGF-1 T3 2.79 1.88, 4.13 < 0.0001
Interaction Co-dominant models
IGF-1*SNP Pinteraction
SNP Variables OR 95% CI P value OR 95% CI P value OR 95% CI P value Raw Adjusteda
ADIPOQ 0 = GG; Cases = 223; Controls = 338 1 = GA; Cases = 26; Controls = 49 2 = AA; Cases = 0; Controls = 2
rs17366568 IGF-1 T1 1.00 1.00
0 = GG/1 = GA 2 = AA IGF-1 T2 0.96 0.57, 1.63 0.89 0.14 0.01, 1.54 0.11
n = 561/n = 75/n = 2 IGF-1 T3 1.62 0.93, 2.82 0.09 0.09 0.01, 0.91 0.04 0.098 0.944
GHRL 0 = TT; Cases = 155; Controls = 234 1 = TC; Cases = 83; Controls = 126 2 = CC; Cases = 11; Controls = 29
rs27647 IGF-1 T1 1.00 1.00
0 = TT /1 = TC 2 = CC IGF-1 T2 0.96 0.50, 1.84 0.89 0.70 0.29, 1.71 0.44
n = 389/n = 209/n = 40 IGF-1 T3 1. 75 0.90, 3.42 0.10 1.13 0.45, 2.86 0.79 0.039 0.312
LEPR 0 = TT; Cases = 90; Controls = 140 1 = TG; Cases = 119; Controls = 193 2 = GG; Cases = 40; Controls = 56
rs970468 IGF-1 T1 1.00 1.00 1.00
0 = TT /1 = TG/2 = GG IGF-1 T2 0.71 0.30, 1.69 0.44 0.95 0.45, 1.97 0.88 1.24 0.29, 5.29 0.77
n = 230/n = 312/n = 96 IGF-1 T3 1.52 0.61, 3.79 0.37 1.42 0.67, 3.02 0.36 0.59 0.13, 2.77 0.50 0.089 0.587
0 = GG; Cases = 201; Controls = 303 1 = GA; Cases = 42; Controls = 83 2 = AA; Cases = 6; Controls = 3
rs12059300 IGF-1 T1 1.00 1.00
0 = GG/1 = GA 2 = AA IGF-1 T2 0.83 0.46, 1.49 0.54 0.96 0.31, 3.04 0.95
n = 504/n = 125/n = 9 IGF-1 T3 1.48 0.82, 2.68 0.19 0.61 0.15, 2.44 0.49 0.003 0.069
MBOAT4 0 = AA; Cases = 53; Controls = 99 1 = AG; Cases = 120; Controls = 176 2 = GG; Cases = 76; Controls = 114
rs13272159 IGF-1 T1 1.00 1.00 1.00 1.00
0 = AA/1 = AG/2 = GG IGF-1 T2 3.92 0.91, 16.97 0.07 0.60 0.27, 1.32 0.60 0.89 0.37, 2.18 0.80
n = 152/n = 296/n = 190 IGF-1 T3 7.16 1.64, 31.25 0.009 1.29 0.57, 2.94 1.29 0.60 0.23, 1.59 0.31 0.027 0.027
NPY 0 = AA; Cases = 214; Controls = 332 1 = AG; Cases = 32; Controls = 53 2 = GG; Cases = 3; Controls = 4
rs16131 IGF-1 T1 1.00 1.00
0 = AA/1 = AG 2 = GG IGF-1 T2 1.14 0.66, 2.00 0.64 0.13 0.03, 0.71 0.02
n = 546 /n = 85/n = 7 IGF-1 T3 1.77 1.00, 3.14 0.05 0.28 0.05, 1.64 0.16 0.004 0.012
POMC 0 = GG; Cases = 209; Controls = 340 1 = GA; Cases = 39; Controls = 48 2 = AA; Cases = 1; Controls = 1
rs7565427 IGF-1T1 1.00 1.00
0 = GG/1 = GA 2 = AA IGF-1T2 1.20 0.70, 2.06 0.52 0.05 0.01, 0.41 0.006
n = 549/n = 87/n = 2 IGF-1T3 1.89 1.07, 3.35 0.03 0.05 0.01, 0.51 0.01 0.079 0.316

The model at the top of the table was not adjusted for potential confounders. The rest of the models were adjusted for IGFBP-3 serum concentration (ng/mL), age (years), genetic ancestry (% Indigenous), BMI (Kg/m2), energy intake (Kcal/day), height (cm), age at menarche (years), ever use oral contraceptives (no,yes), parity (nulliparous, 1 or 2, 3 or more), study (4-CBCS, MBCS), first-degree family history of breast cancer (no, yes), ever alcohol consumption (no, yes) and ever cigarette smoking (no, yes). aBenjamini-Hochberg adjusted P values (correction for the number of SNPs tested per gene); a threshold of 0.2 was considered significant.

HHS Vulnerability Disclosure